Scientific training is in Hematology and Immunology
Dr. Dotti’s scientific training is in hematology and immunology. Since 2000, he has exploited his expertise for the treatment of malignancies using gene modified T lymphocytes. He has a particular interest in strategies that redirect the antigen specificity of T lymphocytes and overcome tumor inhibitory mechanisms, such as development of chimeric antigen receptors, transgenic T-cell receptor, cytokine and cytokine receptor expressions. To add a safety switch to genetically modified T cells, Dr. Dotti contributed in developing a caspase 9 suicide gene inducible by dimerization that has proved safe and successful in clinical trials. He implemented clinical trials in which CAR-redirected T cells have been used to target hematologic malignancies CD19 positive. To reduce the B-cell aplasia caused by CAR.CD19-specific T cells, Dr. Dotti developed an innovative CAR that targets the light chain of human immunoglobulins. This approach is currently in a phase I clinical study. He has also developed a specific expertise in manufacturing clinical grade retroviral vectors. In this role, he has facilitated the development and implementation of over 10 cell therapy trials using gene modified T cells.